TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00522769

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: Girls enrolled in the study will either receive the 6-20 session CBT intervention at the time of enrollment or 6 months after they enroll. Assessments including questions about eating behaviors, mood, and general functioning are given on enrollment in the study, and 3- and 6-months following enrollment (also at 9- and 12-months for those in the delayed treatment condition
Study: NCT00049569

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV
Study: NCT00522769

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: Girls enrolled in the study will either receive the 6-20 session CBT intervention at the time of enrollment or 6 months after they enroll. Assessments including questions about eating behaviors, mood, and general functioning are given on enrollment in the study, and 3- and 6-months following enrollment (also at 9- and 12-months for those in the delayed treatment condition
Study: NCT00049569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asparaginase
Description: Given IM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asparaginase
Description: Given IM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: therapeutic hydrocortisone
Description: Given IT
Study: NCT01242787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LB80380
Description: Optimal dose of LB80380, by oral for 48 weeks (optimal dose will be chosen early 2011 based on the results of LG-BVCL007 study)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entecavir 0.5 mg
Description: Entecavir 0.5 mg, by oral for 48 weeks
Study: NCT02205645

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FibroFix™ Meniscus scaffold
Description: The test article for this study is the FibroFix™ Meniscus scaffold supplied by Orthox Ltd. The FibroFix™ Meniscus scaffold has been developed for repair of defects of the meniscus.~The FibroFix™ Meniscus scaffold used in this study is a silk derived product developed to functionally replace the excised unstable meniscus following a meniscal tear.
Study: NCT04800497

Intervention type: PROCEDURE
Intervention: Hepatic resection
Description: Hepatic resection for HCC
Study: NCT06415630

Intervention type: PROCEDURE
Intervention: Type A aortic dissection surgery
Description: Patients with type A aortic dissection undergone surgery.
Study: NCT04346719

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 10 kHz stimulation (Myomed 932, Enraf-Nonius)
Description: A charge-balanced, symmetric, biphasic sinusoidal current without modulation will be delivered at a frequency of 10 kHz. The stimulation intensity will be defined as that sufficient to produce a strong but comfortable sensation, just below motor threshold, over the median nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft,Netherlands)
Study: NCT03575169

Intervention type: DEVICE
Intervention: BIS Monitor
Description: Unilateral BIS electrode
Study: NCT01138735

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adapalene/benzoyl peroxide
Description: daily topical application for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topical Gel Vehicle
Description: daily topical application for 12 weeks
Study: NCT03913039

Intervention type: PROCEDURE
Intervention: Transperineal biopsy Protocol
Description: 1. Transperineal biopsy approach with avoidance of rectal flora~2. MRI-ultrasound fusion-guided biopsies with reduced number of biopsy cores, where clinically indicated~3. Rectal swab to identify the presence of fluoroquinolone resistant (FQR) bacteria~4. Multi-antibiotic prophylaxis~5. Urine culture, prostate tissue culture and rectal swab culture to define contemporary, region-specific antibiotic resistance patterns.
Study: NCT04553718

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: experimental group
Description: provide mHealth program, which has pregnant women using wearable device and app
Study: NCT04346719

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 20 kHz stimulation (Myomed 932, Enraf-Nonius)
Description: A charge-balanced, symmetric, biphasic sinusoidal current without modulation will be delivered at a frequency of 20 kHz. The stimulation intensity will be defined as that sufficient to produce a strong but comfortable sensation, just below motor threshold, over the median nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft,Netherlands)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation (Myomed 932, Enraf-Nonius)
Description: Sham stimulation will be delivered at a frequency of 10 kHz only during the first 30 seconds.
Study: NCT02660983

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil hydrochloride

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Donepezil matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil hydrochloride
Study: NCT00336648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avastin (Bevacizumab)
Description: 10mg/kg by vein (IV) on Days 1, 2, 15 and 29 the adjuvant therapy every two weeks starting approximately 6 weeks after surgery for three months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 400 mg/m2 IV once a week on Days 1, 2, 8,15, 22, 29, 36 +/-2 days (Saturdays)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Day 3 +/-2 days (Monday) Start Radiation therapy, Mon -Fri x 28 days; 50.4 Gy prescribed to the 95% isodose at 1.8 Gy/fraction (28 fractions)
Study: NCT03382340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imx-110
Description: a nanoparticle encapsulating a Stat3/NF-kB/poly-tyrosine kinase inhibitor and low-dose doxorubicin
Study: NCT01756703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-3995 Low
Description: MT-3995 Low dose for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-3995 High
Description: MT-3995 High dose for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for 8 weeks
Study: NCT05622149

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet Only
Description: Food tracking based on macronutrient goals.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training Only
Description: Subjects completed 16 weeks of supervised resistance training
Study: NCT03464539

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: PG low molecular weight chitosan
Description: The product 1000 mg of Polyglucosamine was administered three times per day before and in between main meals
Study: NCT03519191

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Healthy Relationships Education (HRE)
Description: Healthy Relationships and Economic Pathways involves formal classes in Healthy Relationship Education (HRE), comprehensive case management, and support services and referrals to services.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: HRE+Technology Bootcamp
Description: HRE + Technology Bootcamp involves formal classes in Healthy Relationships Education (HRE), comprehensive case management, support services and referral to services, 6-week intensive website and professional development training, and paid work experience developing a website for a local small business and mentorship.
Study: NCT04103788

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 95% Curcuminoid Powder
Description: 1200 mg curcuminoids

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CurQ+
Description: 400 mg curcuminoids + coconut oil + polysorbate
Study: NCT01877252

Intervention type: PROCEDURE
Intervention: Surgical revascularization

Intervention type: PROCEDURE
Intervention: Surgical revascularization

Intervention type: PROCEDURE
Intervention: Endovascular revascularization

Intervention type: PROCEDURE
Intervention: Endovascular revascularization

Intervention type: OTHER
Intervention: No vascular intervention
Study: NCT02453672

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SB8
Description: SB8, proposed bevacizumab biosimilar

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: EU sourced Avastin®
Description: EU sourced Avastin® (bevacizumab, Roche Registration Ltd.)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: US Sourced Avastin®
Description: US Sourced Avastin® (bevacizumab, Roche Registration Ltd.)
Study: NCT00379301

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency ablation
Description: Special catheters are inserted into blood vessels in the groin, then advanced into the left atrium of the heart. Radiofrequency (heat) energy is applied to small areas of heart tissue where electrical impulses that generate AF are found.
Study: NCT05622149

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet plus Training
Description: Food tracking plus resistance training.
Study: NCT02252263

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elotuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elotuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lirilumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Urelumab
Study: NCT01066377

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Prebiotic and probiotic mix
Description: The probiotic strain will be Bifidobacterium longum bv. infantis CCUG 52486 (10\^8 - 10\^9 live bacteria per day), which was originally isolated from healthy elderly subjects, and which has been demonstrated to have particular ecological fitness and anti-pathogenic effects in vitro. A suitable prebiotic (8g/day) will be selected on the basis of ability to promote optimal growth and survival of this probiotic (inulin, fructooligosaccharides \[FOS\], galactooligosaccharides\[GOS\] and xylooligosaccharides\[XOS\] will be tested).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prebiotic and probiotic mix
Description: The probiotic strain will be Bifidobacterium longum bv. infantis CCUG 52486 (10\^8 - 10\^9 live bacteria per day), which was originally isolated from healthy elderly subjects, and which has been demonstrated to have particular ecological fitness and anti-pathogenic effects in vitro. A suitable prebiotic (8g/day) will be selected on the basis of ability to promote optimal growth and survival of this probiotic (inulin, fructooligosaccharides \[FOS\], galactooligosaccharides\[GOS\] and xylooligosaccharides\[XOS\] will be tested).
Study: NCT02232867

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Arm and Leg Cycling Exercise Program
Description: Participants will perform arm and leg cycling training three times a week, with 30 minutes of aggregate exercise time per session. To evaluate the physiological cost of exercise, heart rate and a rating of perceived exertion will be collected. The progressive element of this training will include increasing the resistance of the ergometer over the six weeks in order to maintain the same relative exercise stress.
Study: NCT03258242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Keluo Xin capsule
Description: four capsules at a time, three times a day, taken orally and consecutively for 24 weeks or 48 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: four placebo capsules at a time, three times a day, taken orally and consecutively for 24 weeks or 48 weeks.
Study: NCT02620280

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin AUC 2 will be given i.v. on day 1 and day 8 q 3 weeks for a total of 8 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC 2 will be given i.v. on day 1 and day 8 q 3 weeks for a total of 8 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abraxane
Description: Abraxane, 125 mg/m2 will be given i.v. on day 1 and day 8 q 3 weeks for a total of 8 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Description: Abraxane, 125 mg/m2 will be given i.v. on day 1 and day 8 q 3 weeks for a total of 8 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MPDL3280A
Description: MPDL3280A, 1200 mg. will be given i.v. infusion on day 1 q 3 weeks for a total of 8 cycles

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Breast cancer surgery (breast and axilla) either conservative or radical not later than 6 weeks

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Breast cancer surgery (breast and axilla) either conservative or radical not later than 6 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anthra
Description: AC or EC (adriamycin or epirubicin and cyclophosphamide) or FEC (fluorouracil, epirubicin, and cyclophosphamide) on day 1 every three weeks for 4 cycles to be delivered after surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anthra
Description: AC or EC (adriamycin or epirubicin and cyclophosphamide) or FEC (fluorouracil, epirubicin, and cyclophosphamide) on day 1 every three weeks for 4 cycles to be delivered after surgery
Study: NCT00734565

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Haemophilus influenzae type b
Description: 1 dose monovalent conjugated vaccine against Haemophilus influenzae type b in children aged 16 - 20 months and infants aged 2 - 4 months
Study: NCT02716740

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Leucine-enriched amino acid supplementation and 30 minutes of physical training 3 times per week
Description: After 3 months of obesity-surgery, if patients lost more than 15% of muscular weight, they will take a leucine-enriched amino acid supplementation during 3 months added with a regular physical training (30 minutes, 3 times/week). Arm A will take 2.46g/day of leucine-enriched amino acid supplementation and arm B 4g/day.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Leucine-enriched amino acid supplementation and 30 minutes of physical training 3 times per week
Description: After 3 months of obesity-surgery, if patients lost more than 15% of muscular weight, they will take a leucine-enriched amino acid supplementation during 3 months added with a regular physical training (30 minutes, 3 times/week). Arm A will take 2.46g/day of leucine-enriched amino acid supplementation and arm B 4g/day.
Study: NCT06491758

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: abvn
Description: A modality of therapy currently being utilized to treat focal or partial seizures that do not respond to seizure medications is called as VNS Therapy (Vagus Nerve Stimulation). This has been approved by FDA as an effective treatment for seizure disorders. Our aim is to study the HRV in patients undergoing this therapy as part of their regular mode of treatment. The specific aim is to measure the HRV in patients undergoing vagus nerve stimulation therapy.~During VNS treatment the stimulator is surgically implanted in the upper chest and stimulation electrodes are implanted in the left cervical vagus nerve.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: abvn
Description: A modality of therapy currently being utilized to treat focal or partial seizures that do not respond to seizure medications is called as VNS Therapy (Vagus Nerve Stimulation). This has been approved by FDA as an effective treatment for seizure disorders. Our aim is to study the HRV in patients undergoing this therapy as part of their regular mode of treatment. The specific aim is to measure the HRV in patients undergoing vagus nerve stimulation therapy.~During VNS treatment the stimulator is surgically implanted in the upper chest and stimulation electrodes are implanted in the left cervical vagus nerve.
Study: NCT06491758

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: abvn
Description: A modality of therapy currently being utilized to treat focal or partial seizures that do not respond to seizure medications is called as VNS Therapy (Vagus Nerve Stimulation). This has been approved by FDA as an effective treatment for seizure disorders. Our aim is to study the HRV in patients undergoing this therapy as part of their regular mode of treatment. The specific aim is to measure the HRV in patients undergoing vagus nerve stimulation therapy.~During VNS treatment the stimulator is surgically implanted in the upper chest and stimulation electrodes are implanted in the left cervical vagus nerve.
Study: NCT03774719

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hand-carried ultrasound
Description: Hand-carried ultrasound of both kidneys to detect the presence or absence of hydronephrosis. Device used will be the lumify portable ultrasound equipped with the C5-2 curved array transducer (Philips, USA).
Study: NCT03445949

Intervention type: DRUG
Group type: OTHER
Intervention: short postimplantation dual antiplatelet therapy
Description: continuing dual antiplatelet therapy up until 6 months after left atrial appendage occlusion with Amplatzer or WATCHMAN device

Intervention type: DRUG
Group type: OTHER
Intervention: short postimplantation dual antiplatelet therapy
Description: continuing dual antiplatelet therapy up until 6 months after left atrial appendage occlusion with Amplatzer or WATCHMAN device

Intervention type: DRUG
Group type: OTHER
Intervention: extended postimplantation dual antiplatelet therapy
Description: stopping dual antiplatelet therapy after 30 days after left atrial appendage occlusion with Amplatzer or WATCHMAN device

Intervention type: DRUG
Group type: OTHER
Intervention: extended postimplantation dual antiplatelet therapy
Description: stopping dual antiplatelet therapy after 30 days after left atrial appendage occlusion with Amplatzer or WATCHMAN device

Intervention type: DRUG
Group type: OTHER
Intervention: long-term treatment with a single antiplatelet agent
Description: continuing long-term treatment with single antiplatelet agent

Intervention type: DRUG
Group type: OTHER
Intervention: long-term treatment with a single antiplatelet agent
Description: continuing long-term treatment with single antiplatelet agent

Intervention type: DRUG
Group type: OTHER
Intervention: 6 months treatment with a single antiplatelet agent
Description: continuing single antiplatelet agent up until 6 months

Intervention type: DRUG
Group type: OTHER
Intervention: 6 months treatment with a single antiplatelet agent
Description: continuing single antiplatelet agent up until 6 months
Study: NCT02897661

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: WMT
Description: Washed microbiota transplantation (WMT) through mid-gut

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: WMT
Description: Washed microbiota transplantation (WMT) through mid-gut

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: EEN
Description: Exclusive enteral nutrition (EEN) through feeding tube

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: EEN
Description: Exclusive enteral nutrition (EEN) through feeding tube
Study: NCT02140593

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Group STANDARD: Rocuronium 0.6 mg/kg followed by bolus rocuronium according to standard treatment combined with saline infusion (placebo).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group DEEP: Rocuronium 0.6 mg/kg followed by rocuronium infusion with target level PTC 0-1 combined with bolus saline (placebo) mimicking standard treatment.
Study: NCT04105491

Intervention type: DEVICE
Intervention: IInvisalign® Aligners
Description: Clear aligner orthodontic treatment
Study: NCT04332458

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: A focus group interview
Description: this is a qualitative study using focus group interviewing.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: A focus group interview
Description: this is a qualitative study using focus group interviewing.
Study: NCT03508908

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: HIV-1 RNA testing
Description: During the intervention period, a blood sample will be obtained and tested for AHI using point-of-care Xpert® HIV Qual assay (Cepheid, Sunnyvale, California, USA). Individuals who test positive will undergo rapid tests to differentiate acute from prevalent HIV infection. Newly diagnosed individuals will be offered immediate ART and assisted partner notification with the HIV-1 RNA testing intervention delivered to partners following the same approach.
Study: NCT02460237

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Disease Screening
Description: Complete HPV self-test

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Disease Screening
Description: Complete HPV self-test

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Receive culturally appropriate instructions for using and returning the HPV self-test device and a photo story information sheet about HPV and HPV self-testing

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Informational Intervention
Description: Receive standard instructions and information sheet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT00194649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miglustat (Zavesca)
Description: 100 mg Miglustat BID (twice daily) for six weeks
Study: NCT02467634

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HuCNS-SC sub-retinal transplantation
Description: HuCNS-SC sub-retinal transplantation in subjects with bilateral GA AMD
Study: NCT03456310

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: transperineal ultrasound
Description: trans-perineal US: B mode capable 2D ultrasound system with cine loop function, a 3.5-6.0 MHz curved array transducer. A mid-sagittal and axial views is obtained by placing a transducer on the perineum (Parting of the labia can improve image quality).~Dynamic MRI:~Magnetic resonance (MR) imaging of the pelvic floor is a two-step process that includes:~analysis of anatomic damage on axial fast spin-echo (FSE) T2-weighted images. then sagittal and coronal (FSE) T2-weighted are obtained.~functional evaluation using sagittal dynamic single-shot T2-weighted sequences during straining and defecation.